« Back |
View printer-friendly version |
Key Points:
- The company presented interim data for its Phase 1b/2 CLASSICAL-Lung study of its pepinemab antibody in combination with avelumab (
Merck KGaA , Darmstadt,Germany ) in NSCLC, which demonstrated a disease control rate (DCR) of 75 percent for all dose escalation subjects, while those who remained on therapy for two months or more showed a 90 percent disease control rate (excludes subjects who were deceased or had rapidly progressing tumors shortly following enrollment). While this is a small sample and comparison across clinical trials are imperfect, single agent avelumab had previously shown 50 percent DCR in a similar NSCLC population. Treatment with the combination therapy was deemed well tolerated at all dose levels. - Initial results of a separate Window-of-Opportunity study in various solid tumors (CRC, melanoma, and HNSCC) being performed at the
Winship Cancer Institute of Emory University showed that pepinemab increased infiltration of CD8+ cytotoxic T-cells and reduced regulatory T cells (Treg) and myeloid derived suppressor cells (MDSC), a balanced response that increases tumoricidal and reduces immunosuppressive activity in the tumor. The company believes that this is important supporting clinical data previously reported only in animal tumor models.
Next Steps:
- Patient recruitment in the phase 2 CLASSICAL-Lung study continues with the goal of enrolling an additional 50 patients in two cohorts: 22 patients who are immunotherapy naïve and 28 patients whose tumors progressed during or following prior immunotherapy.
- The company plans to present additional updates of all ongoing oncology clinical trials at
ASCO 2019 in early June and anticipates topline data for the CLASSICAL–Lung clinical trial in Q4 2019. - The posters may be accessed on the Investor Relations page of the
Vaccinex website (www.vaccinex.com) or directly via the links below:
http://ir.vaccinex.com/phoenix.zhtml?c=253837&p=irol-EventDetails&EventId=5278389
http://ir.vaccinex.com/phoenix.zhtml?c=253837&p=irol-EventDetails&EventId=5278391
http://ir.vaccinex.com/phoenix.zhtml?c=253837&p=irol-EventDetails&EventId=5278390
About Vaccinex, Inc.
Forward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding
Investor Contact
Phone: (646) 597-6979
E-mail: mrice@lifesciadvisors.com
Media Contact
JQA Partners, Inc.
Phone: (917) 885-7378
E-mail: jabraham@jqapartners.com